

Catheter Ablation for Ventricular Arrhythmias in Hypertrophic Cardiomyopathy

Minglong Chen

Nanjing Medical University Hospital Jiangsu Province Hospital, Nanjing, China

Korean Heart Rhythm Society COI Disclosure


Minglong Chen:


The authors have no financial conflicts of interest to disclose concerning the presentation





Introduction

- Hypertrophic cardiomyopathy (HCM) is a genetic disease of the sarcomere characterized by abnormal LV hypertrophy with myocyte disarray.
- The combination of myofibrillar disarray and fibrosis likely generates heterogeneous conduction properties and, together with the vulnerability of the hypertrophied myocardium to supply demand ischemia, creates a potentially arrhythmogenic milieu.












Introduction

- Common forms of VAs associated with H
 CM have been considered to be VF and p
 olymorphic VT.
- HCM is the most common cardiovascular cause of sudden death in competitive athletes. ICDs are the main stay of therap y for prophylaxis against SCD.





Introduction

- However, the occurrence of monomorphic VT is rare in patients with HCM.
- Ablation is generally performed for monomorphic VT that recurs despite antiarrhythmic therapy, particularly with ICD shocks.
- The ablation experience is limited to case reports and small case series of highly selected patients.


2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias

	9711119								
Recommendation for VA ablation in HCM									
	COR	LOE	Recommendation						
	IIa	B-NR	1. In patients with HCM and recurrent monomorphic VT in whom AAD therapy is ineffective or not tolerated, catheter ablation can be useful.						



Case Series 1: Substrate Map and Long-Term Outcomes of Combined EPI and ENDO Ablation


- 10 patients with HCM-related monomorphic VT;
- Preserved LVEF (LVEF of 57% ± 13%);
- Clinical VT induced in 7/10 patients (2 VTs per patient);
- Ablation sites were identified using a combination of entrainment, activation, late/fractionated potential, and pace mapping.





Case Series 1: Substrate Map and Long-Term Outcomes of Combined EPI and ENDO Ablation

- Voltage mapping identified a combination of epicardial and endocardial scars in most patients.
- Combined EPI and ENDO ablation was performed (3 terminated with ablation from EPI and 1 from ENDO).
- During a 3-year follow-up, the freedom from recurrent ICD shocks was 78% (7/9 patients).





EPICARDIAL

Case Series 2: Safety and Feasibility of Catheter Ablation in patients with HCM and VT

- The first large series of consecutive HCM patients undergoing RFCA of VTs.
- 22 patients with HCM and VTs resistant to medical therapy.
- More advanced disease (LVEF 34.3% ± 9.8%).

Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility

Pasquale Santangeli,*§§¶ Luigi Di Biase, MD,*†‡ Dhanunjay Lakkireddy, MD,§ J. David Burkhardt, MD,* Jayasree Pillarisetti, MD,§ Yoav Michowitz, MD,¶ Javier E. Sanchez, MD,* Rodney Horton, MD,*† Prasant Mohanty, MBBS, MPH,* G. Joseph Gallinghouse, MD,* Antonio Dello Russo, MD,¶ Michela Casella, MD,¶ Gemma Pelargonio, MD,¶ Pietro Santarelli, MD,¶ Atul Verma, MD,* Calambur Narasimhan, MD,** Kalyanam Shivkumar, MD,¶ Andrea Natale, MD, FACC, FHRS*†##

From the *Texas Cardiac Arrhythmia Institute at St. David Medical Center and †Department of Biomedical Engineering, University of Texas, Austin, Texas, ‡Department of Cardiology, University of Foggia, Foggia, Italy, §University of Kansas, Kansas City, Kansas, §§Catholic University, Rome, Italy, ¶UCLA Cardiac Arrhythmia Center and Electrophysiology Programs, Los Angeles, California, Catholic University, Rome, Italy, ¶Southlake Regional Health Center, New Market, Ontario, Canada, **Care Hospital, Andhra Pradesh, India, and ¶Stanford University, Palo Alto, California.

BACKGROUND Management of ventricular tachycardia (VT) in patients with hypertrophic cardiomyopathy (HCM) is challenging.

OBJECTIVE The purpose of this study is to assess the value of radiofrequency catheter ablation (RFCA) for the treatment of the VTs in the setting of HCM.

METHODS Twenty-two patients (18 with ICD) with HCM and multiple episodes of VTs resistant to medical therapy underwent RFCA with an open irrigation catheter. Epicardial access was obtained if required. All patients were followed for at least 1 year after RFCA.

RESULTS Mean age was 50.4 \pm 15.3, and mean ejection fraction was 34.3% \pm 9.8%. RFCA was performed endocardially in all patients, while epicardial radiofrequency applications were needed in 13 patients. A previous endocardial ablation was unsuccessful in six patients. At 20 \pm 9 months of follow-up, elimination of VTs reached 73%. No major complication was observed during and after the procedures in all patients.

CONCLUSION Catheter ablation of VTs in patients with hypertrophic cardiomyopathy refractory to medical therapy is safe, feasible, and successful in eliminating VT. Epicardial VT mapping and ablation should be considered as an important access option for the treatment of these patients to increase the success rate.

KEYWORDS Hypertrophic cardiomyopathy; Ventricular tachycardia; Catheter ablation; Outcomes

ABBREVIATIONS ECG = electrocardiogram; EF = ejection fraction; HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter-defibrillator; ICE = intracardiac echocardiography; LV = left ventricle, ventricular; NYHA = New York Heart Association; RF = radiofrequency; RFCA = radiofrequency catheter ablation; RV = right ventricle, ventricular; SD = standard deviation; VT = ventricular tachycardia

(Heart Rhythm 2010;7:1036–1042) $^{\odot}$ 2010 Heart Rhythm Society. All rights reserved.



Case Series 2: Safety and Feasibility of Catheter Ablation in patients with HCM and VT


- Scar-related VTs occurred most often from the LV-RV junctions (60%), the basal (42%) or apical (18%) LV segment level (coinciding with the anatomical regions frequently associated with fibrosis).
- Epicardial ablation was required in almost two-thirds (13/22) of the patients.





Case Series 2: Safety and Feasibility of Catheter Ablation in patients with HCM and VT


- At 20 ± 9 months of follow-up,
 elimination of VTs reached 73%.
- No major complication was observed during and after the procedures in all patients.





Case Series 3: VT associated with dilated-phase HCM


- 5 patients with dilated-phase HCM and monomorphic VT.
- LVDd 57±7.1 mm with reduced EF 36.8
 ±8.1%, 2/5 patients with aneurysm.
- 4/5 suffered from electrical storm.
- 13 monomorphic VTs were targeted for ablation.






Case Series 3: VT associated with dilated-phase HCM

- VT circuits were predominantly distributed in the basal septum and the basal anterior to anterolateral LV.
- In addition to the endocardial ablation, intracoronary ethanol ablation and surgical cryoablation were required in a number of patients (3/5).
- During a 18-month follow-up, 4/5 (80%) patients are free from VT recurrence.






- The thin-walled dyskinetic or akinetic segment can be composed of dense scars with channels of viable myocardium (resembling ischemic substrate).
- Transthoracic contrast echocardiography, left ventriculography, and real-time visualization with ICE can be helpful.
- 15 patients with HCM and apical aneurysm who underwent RFCA for VT.
- Preserved LVEF (LVEF of 64.5% ± 10.5%).




 Sustained monomorphic VTs with an RBBB or LBBB pattern in lead V1 can both occur, and inferior lead consistent with an exit from the apical aneurysm.






- Endocardial RFCA successfully suppress ed the VT at the LVA border (10/15) or within the LVA (2/15). In 2 of 3 patients without LVA at the endocardial site, linear RFCA at the anterior wall of the aneurysmal neck side was successful.
- In only 1 patient, endocardial RFCA of AA was not effective, and epicardial RFCA site was needed.






- VT recurrence was observed in 2 patients (13.3
 %) during the 12-month follow-up period.
- Cardiac tamponade occurred in 1 patient durin g RFCA applications along the septal border of the LVA from the apex to the aneurysmal neck.
- One patient who refused ICD implantation and was discharged without ICD had sudden cardiac death 17 days after RFCA.






Case Report 5: Transapical myectomy and surgical cryoablation for refractory VT due to HCM with apical aneurysm

- When ablation is not possible or is ineffective, surgical approaches could be successful.
- A 44-year old man with HCM and VT despite undergoing catheter ablation.





Case Report 5: Transapical myectomy and surgical cryoablation for refractory VT due to HCM with apical aneurysm



 Resection of a hypertrophied midventricular muscle through an apical incision and surgical cryoablation of the aneurysm border from the epicardial and endocardial surface were performed successfully.




The patient was well without ventricular arrhythmic events at 2 years postoperatively.

Studies	Time	Sample size	Patiennts	LVEF	EPI ablation	Follow-up (M)	Success Rate (%)
Dukkipati SR, et al. Circ Arrhythm Electrophysiol. 2011 Apr;4(2):185-94.	2011	10	HCM-related monomorphic VT; Preserved LVEF	57 ± 13	8/9	37	78 (7/9)
Santangeli P, et al. Heart Rhythm. 2010 Aug;7(8):1 036-42.	2010	22	HCM-related monomorphic VT; Reduced LVEF	34 ± 10	13/22	20	73 (16/22)
Ueda A, et al. Europace. 2012 May;14(5):734-40.	2012	5	Dilated-phase HCM; Monomorphic VT	37 ± 8	3/5	18	80 (4/5)
Igarashi M, et al. JACC Clin Electrophysiol. 2018 Mar;4(3):339-350.	2018	15	HCM and apical aneurysm; Monomorphic VT	65 ± 11	1/15	12	83 (10/12)

- Ablation can be challenging due to the thickness of the myocardium, and epicardial access has been required in the majority of patients.
- VTs associated with apical aneurysms are often ablated endocardially.
- The results of ablation are encouraging, acutely eliminating VT in 80% of patients, with more than two-thirds of patients free of VT in the long-term follow-up.

Other VA Mechanisms

 Although the arrhythmia mechanisms for monomorphic VTs in HCM appear to be mostly scar-related reentry, reports have also mentioned ablation of BBR, focal RVOT, papillary muscle VTs, and left posterior fascicular VT.






Case Example-1: HCM VT case


- Male, 58-year-old
- Prior ICD Implantation becasue of Sustained VT
- NYHA: II-III
- Echo: EF= 60%(Simpson)
- Referred for RFCA of monomorphic VT with ICD storm

Hypertrophic Cardiomyopathy












VT1 TCL=396ms





KHRS 2023

VT1 TCL=396ms






VT1 Terminated by PVC







Voltage Map for EPI




Voltage Map for LV ENDO




Hemodynamically poorly tolerated VT2 TCL=258ms



Diastolic Potential during VT2



Ablation Procedure



Case Example-2: HCM with apical aneurysm

- Male, 51-year-old
- Monomorphic VT with AAD refractory
- NYHA: II
- Echo: EF= 65.4% (Simpson)
- Apical aneurysm in transthoracic contrast echocardiography.

Hypertrophic Cardiomyopathy with Apical Aneurysm




ICE image and left ventriculography of aneurysm






Voltage Map for EPI






Voltage Map for EPI and ENDO






Clinical VT induced TCL=295ms





KHRS 2023

Diastolic Potential during VT (EPI)





Home Messages

 Polymorphic VT and VF are the most common VAs in HCM; monomorphic VT is less common.

- The arrhythmogenic substrate in HCM often involves the septum but can extend to the epicardium, often necessitating combined endocardial and epicardial ablation procedures to eliminate the VT.
- VT associated with apical aneurysms is often ablated endocardially.







Thank you!

Minglong Chen

Nanjing Medical University Hospital Jiangsu Province Hospital, Nanjing, China



